CD317 Signature in Head and Neck Cancer Indicates Poor Prognosis

Journal of Dental Research
L-L YangZ-J Sun

Abstract

Targeted therapy using monoclonal antibodies (mAbs) has emerged as a widely used form of immunotherapy in head and neck squamous cell carcinoma (HNSCC). Membrane-associated glycoprotein CD317 has been preferentially overexpressed by multiple myeloma cells, and its humanized mAb has been previously used in clinical trials. However, overexpression of CD317 in HNSCC and its correlation with tumor immunity is still uncertain. Here, the immunoreactivity of CD317 was detected in human HNSCC tissue microarrays, which contained 43 oral mucosa samples, 48 dysplasia samples, and 165 primary HNSCC. We found that CD317 expression was up-regulated in HNSCC tumor cells, and the CD317 expression level was independent of the histological grade, tumor size, and lymph node metastasis. Moreover, Kaplan-Meier survival curve analysis showed that patients with high expression of CD317 had a poor prognosis compared with patients with low expression. Furthermore, CD317 overexpression in HNSCC was correlated with immune checkpoint molecules PD-L1, B7-H3, and B7-H4 and tumor-associated macrophage markers (CD68 and CD163). We also observed that CD317 was overexpressed in immunocompetent mouse HNSCC tissue compared with normal tissue. Taken together, our ...Continue Reading

References

Dec 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·M B EisenD Botstein
Jun 8, 2004·Bioinformatics·Alok J Saldanha
Sep 24, 2004·Cancer Genetics and Cytogenetics·Gokce A TorunerJames J Dermody
Mar 16, 2007·Neoplasia : an International Journal for Oncology Research·Daniel R RhodesArul M Chinnaiyan
Jun 19, 2007·Cancer Research·Toni M Robinson-SmithAngela F Drew
Jan 18, 2008·Nature·Stuart J D NeilPaul D Bieniasz
Nov 4, 2008·Cancer Immunology, Immunotherapy : CII·Wei WangSaburo Sone
Jul 1, 2009·The Journal of Experimental Medicine·Wei CaoYong-Jun Liu
Dec 20, 2011·Journal of Translational Medicine·Moniek Heusinkveld, Sjoerd H van der Burg
Feb 3, 2012·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Nobuyuki FujiiHisao Ito
Aug 4, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zhi-Jun SunAshok B Kulkarni
Aug 16, 2014·Cancers·Theerawut ChanmeeNaoki Itano
Apr 11, 2015·Cancer Cell·Suzanne L TopalianDrew M Pardoll
Jul 29, 2015·CA: a Cancer Journal for Clinicians·Angela C ChiBrad W Neville
Sep 10, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert L Ferris
May 14, 2016·International Journal of Oncology·Natalie WoodmanSylvain Julien
Jul 8, 2016·Cancer Immunology, Immunotherapy : CII·Lei WuZhi-Jun Sun
Sep 21, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laura Q M ChowTanguy Y Seiwert
Oct 11, 2016·The New England Journal of Medicine·Robert L FerrisMaura L Gillison
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Feb 12, 2017·Cell·Padmanee SharmaAntoni Ribas

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
gene engineering knockout

Software Mentioned

Aperio Quantification
GraphPad Prism
VISTA
TreeView
Cluster

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.